DARZALEX Becomes Europe's First Self-Administered Oncology Injectable
On March 27, 2026, Johnson & Johnson announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) approved a significant label change for its multiple myeloma drug, DARZALEX (daratumumab). The updated label for the subcutaneous (SC) formulation allows patients or their caregivers to administer the treatment at home, starting from the fifth dose. This decision marks a pivotal moment in European oncology, establishing daratumumab as the first-ever injectable cancer therapy approved for self-administration.
The approval covers all ten therapeutic indications for daratumumab SC, including multiple myeloma and light chain (AL) amyloidosis. By offering greater flexibility, the change allows physicians and patients to choose the most appropriate administration setting. This move is expected to improve the quality of life for patients who often face frequent hospital visits for treatment, while also freeing up resources within strained healthcare systems.
Approval Poised to Expand DARZALEX's 748,000-Patient Reach
The at-home administration option fortifies DARZALEX's position as a foundational therapy in the multiple myeloma market, which saw over 35,000 new diagnoses in the European Union in 2022. Since its launch, the drug has been administered to more than 748,000 patients globally. This enhanced convenience is a key competitive advantage that could drive greater patient uptake and adherence, further cementing its market leadership.
Developed under a 2012 exclusive license agreement with Genmab A/S, daratumumab is a CD38-directed antibody that has consistently shown significant efficacy in ten Phase 3 clinical trials. The subcutaneous formulation, which enables this new flexibility, utilizes Halozyme's ENHANZE® drug delivery technology. The approval sets a new standard for patient-centric care in oncology and will likely pressure competitors to develop similar administration options for their own therapies.
